Clinical trial considerations on male contraception and collection of pregnancy information from female partners.
BACKGROUND
There is little guidance regarding the risk of exposure of pregnant women/ women of childbearing potential to genotoxic or teratogenic compounds via vaginal dose delivered through seminal fluid during sexual intercourse.


METHODS
We summarize current thinking and provide clinical trial considerations for a consistent approach to contraception for males exposed to genotoxic and/or teratogenic compounds or to compounds of unknown teratogenicity, and for collection of pregnancy data from their female partners.


RESULTS
Where toxicity testing demonstrates genotoxic potential, condom use is required during exposure and for 5 terminal plasma half-lives plus 74 days (one human spermatogenesis cycle) to avoid conception.For non-genotoxic small molecules and immunoglobulins with unknown teratogenic potential or without a no observed adverse effect level (NOAEL) from embryo-fetal development (EFD) studies and no minimal anticipated biological effect level (MABEL), condom use is recommended for males with pregnant partner/female partner of childbearing potential. For teratogenic small molecules with estimated seminal fluid concentration and a margin between projected maternal area under the curve (AUC) and NOAEL AUC from EFD studies of ≥300 (≥100 for immunoglobulins) or in the absence of a NOAEL with a margin between MABEL plasma concentration and maternal Cmax of ≥300 (≥10 for immunoglobulins), condom use is not required. However, condom use is required for margins below the thresholds previously indicated. For small molecules with available seminal fluid concentrations, condom use is required if margins are <100 instead of <300. Condom use should continue for as long as the projected margin is at or above the defined thresholds. Pregnancy data should be proactively collected if pregnancy occurs during the condom use period required for males exposed to first-in-class molecules or to molecules with a target/class shown to be teratogenic, embryotoxic or fetotoxic in human or preclinical experiments.


CONCLUSIONS
These recommendations, based on a precaution principle, provide a consistent approach for minimizing the risk of embryo-fetal exposure to potentially harmful drugs during pregnancy of female partners of males in clinical trials. Proactive targeted collection of pregnancy information from female partners should help determine the teratogenic potential of a drug and minimize background noise and ethical/logistical issues.
Safety Risk Management, Licensing & Early Development, F. Hoffmann-La Roche AG Ltd, Basel, CH, Switzerland. maria.longauer_banholzer@roche.com
Maria Longauer
ML
Banholzer
Heinrich
H
Buergin
Christoph
C
Wandel
Georg
G
Schmitt
Elmar
E
Gocke
Richard
R
Peck
Thomas
T
Singer
Theresa
T
Reynolds
Marie
M
Mannino
Jonathan
J
Deutsch
Lucette
L
Doessegger
D002986:Clinical Trials as Topic; D017280:Condoms; D003267:Contraception / Q000706:statistics & numerical data*; D003625:Data Collection / Q000706:statistics & numerical data*; D003663:Decision Trees; D005260:Female; D006801:Humans; D008297:Male; D011247:Pregnancy; D012747:Sexual Partners